European Private Hospital Awards (EPHA) 2025
The winner in the category: Excellence in Health Tech Innovation
HLA La Vega hospital has developed the Ariza-Pallares method for CryoEbos, a revolutionary technique that improves the diagnosis of mediestinal cancer through safer and more accurate biopsies.
Already adopted in 13 countries, this innovation enables comprehensive molecular diagnostics, personalized treatments and a remarkable improvement in patient survival. A breakthrough that brings precision and life together.
What makes your project so special?
Our project, the Ariza-Pallarés method for CRYOEBUS, represents a breakthrough in mediastinal disease diagnosis. By combining cryobiopsy with endobronchial ultrasound guidance, we achieve higher-quality tissue samples, enabling earlier and more accurate diagnoses. This innovation reduces patient risk, lowers healthcare costs, and facilitates access to targeted therapies, ultimately improving survival rates. It is a clear example of how clinical research can be transformed into real value for patients.
What does this award mean to you and your teams?
This award is a recognition of our commitment to excellence, teamwork, and patient-centered innovation. For HLA La Vega, it validates years of research and collaboration aimed at improving diagnostic precision and safety. It motivates us to continue leading technological advances in healthcare and reinforces our mission to deliver cutting-edge medicine that truly makes a difference in patients’ lives.
The project
This initiative introduces the Ariza–Pallarés Method for performing CRYOEBUS (cryobiopsy under endobronchial ultrasound guidance), a groundbreaking technique developed at HLA La Vega Hospital. It enhances the diagnostic performance in mediastinal tumors, lymphomas, and other diseases.
Objectives:
-Achieve 100% molecular diagnostic yield for biomarkers (PD-L1, EGFR, ALK).
-Improve sensitivity to over 95% in mediastinal malignancies.
-Reduce complications and procedure-related risks.
-Expand global adoption of this minimally invasive method.
Expected Results:
-Broader access to targeted oncology therapies.
-Increased survival through earlier and more precise diagnosis.
-Safer and more effective biopsies of the mediastinum.
Replay the sequence
